Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy
| Autor: | George K. K. Lau, Wing-Yan Au, A. K. W. Lie, Yok-Lam Kwong, Yui-Hung Yueng, HY Zhang, Benjamin Cy Wong, Winnie W.W. Cheung, Nancy Leung, Raymond Liang, Chee-Kin Hui |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
Male Hepatitis B virus medicine.medical_specialty HBsAg medicine.medical_treatment Antineoplastic Agents medicine.disease_cause Antiviral Agents Gastroenterology Hepatitis Immunocompromised Host Lamivudine-therapeutic-use Internal medicine Hematologic-Neoplasms-drug-therapy Humans Medicine Letters Risk factor Aged Chemotherapy Hepatitis B Surface Antigens Reverse-transcriptase inhibitor business.industry Lamivudine Hepatitis-B-prevention-and-control Middle Aged Hepatitis B medicine.disease Hematologic Neoplasms DNA Viral Immunology Female Virus Activation Virus-Activation-drug-effects Viral disease business Hepatitis-B-virus-physiology Follow-Up Studies medicine.drug |
| Zdroj: | Gut. 54:1597-1603 |
| ISSN: | 0017-5749 |
| DOI: | 10.1136/gut.2005.070763 |
| Popis: | Background: The hepatic outcome of hepatitis B surface antigen (HBsAg) positive patients undergoing chemotherapy after withdrawal of pre-emptive lamivudine is unknown. Aims: To examine the occurrence of hepatitis B virus (HBV) reactivation after withdrawal of pre-emptive lamivudine. Methods: Pre-emptive lamivudine was started one week before initiation of chemotherapy in 46 consecutive HBsAg positive patients and continued for the entire duration of chemotherapy. Pre-emptive lamivudine was stopped at a median 3.1 (range 3.0-3.4) months after completion of chemotherapy. Patients were longitudinally followed up after withdrawal of pre-emptive lamivudine. Results: Median time of follow up after withdrawal of lamivudine was 25.7 (range 5.7-75.7) months. Eleven of the 46 patients (23.9%) developed HBV reactivation after withdrawal of pre-emptive lamivudine. Eight of the 16 patients with high pre-chemotherapy HBV DNA (≥10 4 copies/ml) compared with three of the 30 patients with low pre-chemotherapy HBV DNA ( published_or_final_version |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|